Jane A Endicott

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9511727/publications.pdf

Version: 2024-02-01

87	11,176	38660 50	58464 82
papers	citations	h-index	g-index

202	202	202	11186
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Biochemistry of P-Glycoprotein-Mediated Multidrug Resistance. Annual Review of Biochemistry, 1989, 58, 137-171.	5.0	2,051
2	Protein Kinase Inhibitors: Insights into Drug Design from Structure. Science, 2004, 303, 1800-1805.	6.0	1,164
3	Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biology, 1999, 1, 60-67.	4.6	752
4	Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature, 1986, 324, 485-489.	13.7	677
5	The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nature Cell Biology, 1999, 1, 438-443.	4.6	509
6	The Structural Basis for Control of Eukaryotic Protein Kinases. Annual Review of Biochemistry, 2012, 81, 587-613.	5.0	362
7	Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nature Structural Biology, 1997, 4, 796-801.	9.7	243
8	Molecular Basis for the Recognition of Phosphorylated and Phosphoacetylated Histone H3 by 14-3-3. Molecular Cell, 2005, 20, 199-211.	4.5	220
9	Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles. Journal of Medicinal Chemistry, 2000, 43, 2797-2804.	2.9	203
10	Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity. Journal of Biological Chemistry, 1999, 274, 8746-8756.	1.6	198
11	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology, 2002, 9, 745-749.	9.7	198
12	CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene, 2008, 27, 5797-5807.	2.6	165
13	Structural insights into the functional diversity of the CDKâ€“cyclin family. Open Biology, 2018, 8, .	1.5	156
14	CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nature Communications, 2015, 6, 6769.	5.8	145
15	Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex. Journal of Medicinal Chemistry, 2008, 51, 737-751.	2.9	144
16	Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects. Journal of Medicinal Chemistry, 2003, 46, 222-236.	2.9	139
17	Inhibitor Binding to Active and Inactive CDK2. Structure, 2001, 9, 389-397.	1.6	137
18	Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. Cancer Cell, 2013, 23, 618-633.	7.7	136

#	Article	IF	Citations
19	Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Proteinâ˜Protein Interaction: Structureâ˜Activity Studies Leading to Improved Potency. Journal of Medicinal Chemistry, 2011, 54, 1233-1243.	2.9	130
20	N2-SubstitutedO6-CyclohexylmethylguanineDerivatives:Â Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2. Journal of Medicinal Chemistry, 2004, 47, 3710-3722.	2.9	116
21	Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structureâ€“Activity Relationship, and Anticancer Activities. Journal of Medicinal Chemistry, 2013, 56, 640-659.	2.9	111
22	Cyclin-dependent kinases: inhibition and substrate recognition. Current Opinion in Structural Biology, 1999, 9, 738-744.	2.6	109
23	The cyclin box fold: protein recognition in cell-cycle and transcription control. Trends in Biochemical Sciences, 1997, 22, 482-487.	3.7	105
24	Meriolins, a New Class of Cell Deathâ€“Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases. Cancer Research, 2007, 67, 8325-8334.	0.4	103
25	Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction. Journal of the American Chemical Society, 2008, 130, 16038-16044.	6.6	102
26	The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4171-4176.	3.3	102
27	Structure-based design of cyclin-dependent kinase inhibitors. , 2002, 93, 125-133.		96
28	Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 511-519.	1.1	96
29	Structures of P. falciparum PfPK5 Test the CDK Regulation Paradigm and Suggest Mechanisms of Small Molecule Inhibition. Structure, 2003, 11, 1329-1337.	1.6	91
30	Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 withO6-Substituted Guanine Derivatives. Journal of Medicinal Chemistry, 2002, 45, 3381-3393.	2.9	90
31	Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB. Chemistry and Biology, 2010, 17, 931-936.	6.2	90
32	Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain. EMBO Journal, 2005, 24, 3178-3189.	3.5	87
33	Cyclin-Dependent Kinase Inhibition by New C-2 Alkynylated Purine Derivatives and Molecular Structure of a CDK2â˜Inhibitor Complex. Journal of Medicinal Chemistry, 2000, 43, 1282-1292.	2.9	86
34	How Tyrosine 15 Phosphorylation Inhibits the Activity of Cyclin-dependent Kinase 2-Cyclin A. Journal of Biological Chemistry, 2007, 282, 3173-3181.	1.6	85
35	Identification and Characterization of an Irreversible Inhibitor of CDK2. Chemistry and Biology, 2015, 22, 1159-1164.	6.2	85
36	Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 132-150.	1.1	78

#	Article	IF	Citations
37	Cyclin-Dependent Kinase (CDK) Inhibitors: Structureâ€“Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. Journal of Medicinal Chemistry, 2017, 60, 1746-1767.	2.9	77
38	Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition. Cell Chemical Biology, 2019, 26, 121-130.e5.	2.5	72
39	Cyclin-dependent kinase homologues of Plasmodium falciparum. International Journal for Parasitology, 2002, 32, 1575-1585.	1.3	71
40	Structure-Based design of 2-Arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-Dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3079-3082.	1.0	69
41	Structures of the Dsk2 UBL and UBA domains and their complex. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 177-188.	2.5	69
42	CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes and Cancer, 2010, 1, 369-380.	0.6	67
43	A Code for RanGDP Binding in Ankyrin Repeats Defines a Nuclear Import Pathway. Cell, 2014, 157, 1130-1145.	13.5	67
44	Searching for Cyclin-Dependent Kinase Inhibitors Using a New Variant of the Cope Elimination. Journal of the American Chemical Society, 2006, 128, 6012-6013.	6.6	64
45	Structures of P. falciparum Protein Kinase 7 Identify an Activation Motif and Leads for Inhibitor Design. Structure, 2008, 16, 228-238.	1.6	62
46	FragLitesâ€”Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation. Journal of Medicinal Chemistry, 2019, 62, 3741-3752.	2.9	62
47	Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. , 2002, 93, 113-124.		61
48	Structure of Rpn10 and Its Interactions with Polyubiquitin Chains and the Proteasome Subunit Rpn12*. Journal of Biological Chemistry, 2010, 285, 33992-34003.	1.6	61
49	Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Sequence, 1991, 2, 89-101.	0.7	60
50	The structure of an MDM2â€“Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 1358-1366.	2.5	59
51	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 217-222.	1.0	54
52	N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Molecular Cancer Therapeutics, 2008, 7, 2713-2724.	1.9	51
53	Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity. Journal of Medicinal Chemistry, 2013, 56, 660-670.	2.9	51
54	Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System. Cell Reports, 2017, 21, 1386-1398.	2.9	49

#	Article	IF	Citations
55	The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508. ACS Chemical Biology, 2012, 7, 811-816.	1.6	45
56	A procedure for setting up high-throughput nanolitre crystallization experiments. II. Crystallization results. Journal of Applied Crystallography, 2003, 36, 315-318.	1.9	43
57	Dissecting the Determinants of Cyclin-Dependent Kinase 2 and Cyclin-Dependent Kinase 4 Inhibitor Selectivityâ€. Journal of Medicinal Chemistry, 2006, 49, 5470-5477.	2.9	39
58	Structure-based discovery of cyclin-dependent protein kinase inhibitors. Essays in Biochemistry, 2017, 61, 439-452.	2.1	39
59	MDM2-p53 proteinâ€“protein interaction inhibitors: A-ring substituted isoindolinones. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5916-9.	1.0	36
60	Structural characterization of the cyclin-dependent protein kinase family. Biochemical Society Transactions, 2013, 41, 1008-1016.	1.6	35
61	Chemical Inhibitors of Cyclin-Dependent Kinases. , 1999, 82, 269-278.		33
62	The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b. Structure, 2012, 20, 1788-1795.	1.6	32
63	Cyclin-dependent kinase inhibitors. Progress in Cell Cycle Research, 2003, 5, 235-48.	0.9	31
64	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2021, 64, 4071-4088.	2.9	30
65	Budding yeast Dsk2 protein forms a homodimer via its C-terminal UBA domain. Biochemical and Biophysical Research Communications, 2005, 336, 530-535.	1.0	28
66	Exploiting structural principles to design cyclin-dependent kinase inhibitors. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 58-64.	1.1	27
67	An Inhibitorâ€™s-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States. ACS Chemical Biology, 2014, 9, 1251-1256.	1.6	27
68	A new crystal form of Lys48-linked diubiquitin. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 994-998.	0.7	26
69	Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation. Biochemical Journal, 2012, 448, 55-65.	1.7	23
70	Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. Organic and Biomolecular Chemistry, 2007, 5, 1577.	1.5	16
71	Understanding Smallâ€Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy. Chemical Biology and Drug Design, 2011, 77, 301-308.	1.5	15
72	8-Substituted O⁶-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode. Journal of Medicinal Chemistry, 2014, 57, 56-70.	2.9	15

#	Article	IF	Citations
73	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach. Organic and Biomolecular Chemistry, 2018, 16, 1843-1850.	1.5	15
74	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38Î± and BRD4. European Journal of Medicinal Chemistry, 2019, 178, 530-543.	2.6	15
75	Structural principles in cell-cycle control: beyond the CDKs. Structure, 1998, 6, 535-541.	1.6	14
76	Methods for Preparation of Proteins and Protein Complexes That Regulate the Eukaryotic Cell Cycle for Structural Studies. , 2005, 296, 219-236.		13
77	Inhibition of the cell cycle with chemical inhibitors: A targeted approach. Seminars in Cell and Developmental Biology, 2005, 16, 369-381.	2.3	13
78	Chatterboxes: the structural and functional diversity of cyclins. Seminars in Cell and Developmental Biology, 2020, 107, 4-20.	2.3	11
79	Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation. Journal of Molecular Biology, 2021, 433, 166795.	2.0	10
80	An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-ÎºB-Inducing Kinase. Journal of Medicinal Chemistry, 2021, 64, 10001-10018.	2.9	9
81	Multidrug Resistance and P-Glycoprotein Expression. , 1988, , 197-209.		9
82	The role of structure in kinase-targeted inhibitor design. Current Opinion in Drug Discovery & Development, 2004, 7, 428-36.	1.9	6
83	The Ubiquitin-associated (UBA) 1 Domain of Schizosaccharomyces pombe Rhp23 Is Essential for the Recognition of Ubiquitin-proteasome System Substrates Both in Vitro and in Vivo*. Journal of Biological Chemistry, 2012, 287, 42344-42351.	1.6	5
84	Xenopus Phospho-CDK7/Cyclin H Expressed in Baculoviral-Infected Insect Cells. Protein Expression and Purification, 2001, 23, 252-260.	0.6	4
85	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 6513-6540.	2.9	3
86	Structural biology of cell-cycle proteins. Drug Discovery Today: TARGETS, 2004, 3, 136-142.	0.5	2
87	Pass the protein. Nature, 2007, 445, 375-376.	13.7	0